What's the difference between what Conductive Composites is and what Integral Technologies is supposed to be? One can move product and one is always on the edge of a boom. I took most of my profits but am still getting irritated by the empty promises these guys keep coming up with. Is Integral a front for Conductive Composites? I would love to call these guys out in a Conference Call.
I give it 3000-3500 cycles. But each year, losing 2-4 percent depending on conditions. The 10kWh will become an 8 kWh in the later years, and less. Ion Plating occurs when charging at lower temperatures. Should work for 10 years with an unknown capacity state
a123 lIFEPO4 cells were tested to 8000 cycles with 79% capacity using 1C cycling.
I can't help but wonder that there was a link with the loss of Raytheon $9M VGA order from eMagin to Kopin. All is fair in love and war.
If you are talking about the S&p 500 it is less than 1%. Insolvent means more debt than assets. Going through
Life on credit cards eventually catches up to you. They have no money to invest in e, every year that goes by their search technology gets more outdated.
Sentiment: Strong Sell
"It was in Spexs interest to delay, darken, and flat out fool shareholders so they wouldn't dump their stock"
Well, unless you for sure know something others don't, in no way whatsoever can I agree with this. There's a lot of insinuation here.
BS! Nice how you used the word "inking", mmmmmm, ploink, mmmmm, I see the word inks in ploinks. BS!
I like how the bashers stay out of threads like this when a long has a melt down. They know their work has taken effect.
what do you think about this latest financing? I believe this Lincoln Park agreement has been a long time coming it was just held up by the SB fiasco?
Yahoo Finance just increased Sirius XM one year estimate to $ 4.43 from $ 4.38. Oh yeah baby !!!!!
Sentiment: Strong Buy
Complete enrollment in the ongoing pivotal global Phase 3 clinical trial of aldoxorubicin as a second-line treatment for STS in the first quarter of 2016, with PFS data announced in second half of 2016
Report further results from ongoing Phase 2 clinical trial of aldoxorubicin in patients with unresectable GBM
Complete enrollment in the ongoing Phase 1b clinical trial with a combination of aldoxorubicin and ifosfamide/mesna as first-line treatment for advanced sarcomas in the second half of 2015
Complete enrollment in the ongoing Phase 1b clinical trial with a combination of aldoxorubicin and gemcitabine in metastatic solid tumors in the second half of 2015
Complete enrollment in the ongoing Phase 2b clinical trial of aldoxorubicin in relapsed/refractory small cell lung cancer in the first quarter of 2016, with PFS data expected by the second half of 2016
Announce 1-2 new oncology pipeline drug candidates, which utilize novel linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors, in 2015 or early 2016
Sentiment: Strong Buy